SCHEMBL16235396

SCHEMBL16235396

O=S(=O)(Cc1cccc(Cl)c1Cl)Nc1nnc(Cl)cc1O

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ S100A9 P06702 7/20 0.39
▸ AKR1B1 P15121 1/20 0.38
▸ TSHR P16473 1/20 0.36
▸ PTGES2 Q9H7Z7 1/20 0.34
▸ CCR4 P51679 1/20 0.34
▸ PNMT P11086 1/20 0.34
▸ NR1I2 O75469 2/20 0.34
▸ CD38 P28907 1/20 0.34
▸ CXCR2 P25025 1/20 0.34
▸ CA1 P00915 1/20 0.33
▸ ACHE P22303 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16235459 0.90 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL16235155 0.81 S100A9 (0.62) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL16235649 0.81 ERCC1 (0.52) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL16235061 0.79 S100A9 (0.55) ALDH1A1S100A9
SCHEMBL16235457 0.77 S100A9 (0.40) S100A9
SCHEMBL16235961 0.77 S100A9 (0.51) SMN1; SMN2S100A9TSHRPTGES2
SCHEMBL16235308 0.76 S100A9 (0.59) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL16234963 0.76 ALDH1A1 (0.48) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL16235097 0.75 S100A9 (0.67) KDM4ES100A9
SCHEMBL16235089 0.72 S100A9 (0.47) ALDH1A1KDM4EHPGDHSD17B10S100A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-11-13 — — US claimed
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2018-06-07 — — US claimed
US-9873687-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-01-23 — — US claimed
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-04-28 — — US claimed
EP-2925743-B1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-02-03 — — EP claimed
EP-2925743-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS Active Biotech AB (SE) 2015-10-07 — — EP claimed
WO-2014184234-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2014-11-20 — — WO claimed
US-20220378763-A1 COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM CALPROTECT AB (SE) 2022-12-01 — — US disclosed
WO-2020260692-A1 COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM CALPROTECT AB (SE) 2020-12-30 — — WO disclosed
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-11-13 — — US disclosed
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2018-06-07 — — US disclosed
US-9873687-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-01-23 — — US disclosed
US-9873687-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-01-23 — — US disclosed
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-04-28 — — US disclosed
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-04-28 — — US disclosed
EP-2925743-B1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-02-03 — — EP disclosed
EP-2925743-B1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-02-03 — — EP disclosed
EP-2925743-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS Active Biotech AB (SE) 2015-10-07 — — EP disclosed
WO-2014184234-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2014-11-20 — — WO disclosed
WO-2014184234-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2014-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220378763-A1 COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM TNNT2, TNNI3, HMGB1 ALDH1A1 2241/4885KDM4E 3120/4885HPGD 393/4885
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors S100A9, S100B, S100A10 ALDH1A1 4109/4885KDM4E 3512/4885HPGD 3564/4885
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100B, S100A10 ALDH1A1 4109/4885KDM4E 3512/4885HPGD 3564/4885
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100A4, S100B ALDH1A1 4370/4885KDM4E 3670/4885HPGD 2406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback